[go: up one dir, main page]

WO1987002670A1 - Procede d'utilisation de bar1 pour la secretion de proteines etrangeres - Google Patents

Procede d'utilisation de bar1 pour la secretion de proteines etrangeres Download PDF

Info

Publication number
WO1987002670A1
WO1987002670A1 PCT/US1986/002198 US8602198W WO8702670A1 WO 1987002670 A1 WO1987002670 A1 WO 1987002670A1 US 8602198 W US8602198 W US 8602198W WO 8702670 A1 WO8702670 A1 WO 8702670A1
Authority
WO
WIPO (PCT)
Prior art keywords
barl
promoter
fragment
gene
plasmid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1986/002198
Other languages
English (en)
Inventor
Vivian L. Mackay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Priority to SU864203156A priority Critical patent/RU2091490C1/ru
Priority to UA4203156A priority patent/UA41863C2/uk
Priority to HU865248A priority patent/HU206897B/hu
Priority to IE280486A priority patent/IE63822B1/en
Priority to DE3689918T priority patent/DE3689918T2/de
Priority to AT86114769T priority patent/ATE107357T1/de
Priority to EP86114769A priority patent/EP0220689B1/fr
Priority to ES86114769T priority patent/ES2056785T3/es
Priority to CN86107554A priority patent/CN1027179C/zh
Priority to CS867764A priority patent/CZ284251B6/cs
Priority to SK7764-86A priority patent/SK776486A3/sk
Publication of WO1987002670A1 publication Critical patent/WO1987002670A1/fr
Priority to DK320287A priority patent/DK320287A/da
Priority to FI872801A priority patent/FI872801A0/fi
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
    • C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
    • C12N15/815—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts for yeasts other than Saccharomyces
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/58—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi
    • C12N9/60—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from fungi from yeast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Definitions

  • the present invention is directed to novel DNA constructs containing at least the translated signal peptide portion of the Saccharomvces cerevisiae BARl gene and at least one structural gene foreign to a host cell transformed with said construct. Transformation of host organisms by such constructs will result in expression of a primary translation product comprising the structural protein encoded by the foreign gene fused to the signal peptide of BARl so that the protein is processed through the host cell secretory pathway and may be secreted from the host cell into the culture medium or the periplasmic space.
  • Various procaryotic and eucaryotic microorganisms have been utilized as hosts for production of heterologous polypeptides, i.e., polypeptides which are not naturally produced by the host, by way of re ⁇ ombinant DNA methodology.
  • Various eucaryotic fungal species are of particular interest, including Saccharomvces cerevisiae, Schizosaccharomyces pombe, Aspergillus and Neurospora.
  • Saccharomvces cerevisiae Saccharomvces cerevisiae
  • Schizosaccharomyces pombe Aspergillus and Neurospora.
  • Much work has been done in the budding yeast S. cerevisiae.
  • Yeast cells when transformed with a suitable DNA construct, such as a plasmid, have been made to express heterologous genes contained in the plasmid.
  • S. cerevisiae is known to secrete some of its naturally produced proteins, although knowledge of the process is quite limited compared to what is known about secretion of proteins from bacteria and mammalian cells. It appears that most of the secreted yeast proteins are enzymes which remain in the periplasmic space, although the enzymes invertase and acid phosphatase may also be incorporated into the cell wall.
  • the proteins which are known to be secreted into the culture medium by S. cerevisiae include the mating pheromones (o-factor and a-factor), killer toxin, and the protein accounting for Barrier activity (hereinafter "Barrier"). Secretion through the cell wall into the medium is also referred to as "export". S.
  • ⁇ -factor comprising a precursor polypeptide that is cleaved from mature ⁇ -factor
  • non-translated gene sequences including promoter and regulatory regions
  • Another object of the present invention is to provide a method for producing foreign proteins which are secreted from a microbial host.
  • the present invention is directed to DNA constructs and methods for using same, which constructs comprise at least the signal peptide coding sequence of the Saccharomyces cerevisiae BARl gene, at least one structural gene foreign to the host organism, and a promoter which controls the expression in a host organism of a fusion protein comprising the BARl signal peptide and the foreign protein.
  • FIG. 3 illustrates the construction of plasmid p254
  • the structural BARl gene, or a portion thereof, and the structural gene to be expressed will preferably be under control of a single promoter. Methods of ligation of DNA fragments are amply described and are well within the ability of those with ordinary skill in the art to perform.
  • the DNA coding sequence of the protein to be expressed may be essentially that of any protein, particularly proteins of commercial importance, such as interferons, insulin, proinsulin, ⁇ -1-antitrypsin, growth factors, and tissue plasminogen activator.
  • the different steps can be conveniently done in microtiter dishes, until the pellets are transferred to the scintillation vials.
  • A. recombinant plasmid pool comprising the entire yeast genome was constructed (Nasmyth and Tat ⁇ hell, Cell 19: 753-764, 1980) using the shuttle vector YEp13 (Broach et al., Gene 8: 121-133, 1979). Yeast DNA fragments, produced via a partial Sau 3A digestion, were inserted into Bam Hi-digested YEp13.
  • the plasmid pool was used to transform S . cerevisiae strain XP635-10C (MATa leu2-3 leu2-112 bar1-1 ga12: ATCC #20679) and transformants were selected for leucine prototrophy and growth on a concentration of ⁇ -factor that is inhibitory to the a barl cells. Resultant colonies were then screened for the ability to secrete Barrier activity. Two colonies were found which carried both leucine independence and the ability to secrete Barrier. These colonies carried the plasmids designated pBAR2 and pBAR3.
  • pBAR3 plasmid insert comprised a portion of the insert of pBAR2, but oriented in the vector in the opposite direction.
  • Further subcloning and screening for Barrier secretion localized the functional BARl gene sequence to a region of approximately 2.75 kb. This fragment comprises the coding sequence, nontranslated transcribed sequences, promoter, regulatory regions, transcription terminator, and flanking chromosomal sequences.
  • the plasmid pBAR2 was digested with restriction endonucleases Hind III and Xho I and a fragment of approximately 3 kb was purified by electrophoresis through an agarose gel. This fragment was inserted into plasmid pUC13 which had been digested with Hind III and Sal I.
  • the resulting recombinant plasmid, desig nated pZV9 (FIG. 2), can be used to transform E. coli, but lacks the necessary origin of replication and selectable marker for a yeast vector.
  • the plasmid pZV9, in a transformant strain of E. coli RRI has been deposited with ATCC under accession no. 53283.
  • fragments of the BARl gene comprising the 5' regulatory region and a portion of the coding sequence were used.
  • the fusion of the BARl and proinsulin gene fragments was made in the proper reading frame and at a point in the BARl sequence at which the resulting fusion polypeptide may be cleaved, preferably in vivo.
  • Several sites in the BARl gene are potential cleavage sites; the Arg-Arg at position 177-178 was selected as the test site of fusion with proinsulin.
  • the 5' regulatory sequences and approximately 800 bp of the coding sequence of BARl were purified from plasmid pZV9 as a 1.9 kb Hind Ill-Sal I fragment.
  • FIG. 3 there is shown a method for subcloning human preproinsulin cDNA.
  • a human preproinsulin cDNA (preBCA clone), p27, is produced by G-tailing Pst I digested pBR327 and inserting C-tailed DNA, made by reverse transcribing total RNA from human pancreas. Plasmid pBR327 is described by Soberon et al., Gene 9: 287-305 (1980) and the sequence of human preproinsulin is reported by Bell et al., Nature 232: 525-527 (1979). The complete translated sequence was cut out as a Nco I-Hga I fragment.
  • plasmids were screened for the presence of Eco RI, Nco I and Xba I sites flanking a 340 bp insert.
  • a plasmid having these properties is termed p47, shown in FIG. 3.
  • a proinsulin (BCA) fragment with a blunt 5' end was generated by primer repair synthesis (Lawn et al., Nuc. Acids Res. 9: 6103-6114, 1981) of plasmid p47.
  • Subsequent digestions with Xba I yielded a 270 bp fragment which was inserted into pUC12.
  • the vector was prepared by cutting with Hind III, blunting the ends with DNA polymerase I (Klenow fragment), cutting with Xba I, and gel purifying.
  • the resultant vector fragment comprising a blunt end and a Xba I sticky end, was ligated to the above described BCA fragment.
  • GGTCGACC T4 polynucleotide kinase and ⁇ - 32 P-ATP and were ligated to the blunted proinsulin fragment.
  • the proinsulin fragment and the 1.9 kb BARl fragment were ligated together into pUC13 which had been digested with Hind III and Bam HI. This construct was used to transform E. coli K12 (JM83).
  • Transformed cells were screened for ampicillin resistance and production of white colonies. Further screening by restriction endonuclease digestion using Hind III, Bam HI, and Sal I identified a plasmid (pZV27) containing a Hind III-Bam HI fragment of the proper size and a single Sal I site.
  • plasmid pZV27 was digested with Hind HI and Bam HI and the ca. 2.2 kb BARl-proinsulin fusion fragment was gel purified. This fragment was then inserted into the replicative form of the phage vector M13mpll (Messing, Meth.
  • kinased primer 7.5 pmol was then combined with 80 ng of M13 sequencing primer (Bethesda Research Laboratories, Inc.) This mixture was annealed to 2 ⁇ g of single stranded mpll-ZV29 and the second strand was extended using T4 DNA ligase and DNA polymerase I (Klenow fragment), as described for oligonucleotidedirected mutagenesis (two primer method) by Zoller et al. (Manual for Advanced Techniques in Molecular Cloning Course, Cold Spring Harbor Laboratory, 1983). DNA prepared in this way was used to transfect E. coli K12 (JM103) and plaques were screened using the kinased oligomer as probe (Zoller et al..
  • Plaques so identified were used for preparation of phage replicative form (RF) DNA (Messing, ibid.). Restriction enzyme digestion of RF DNA identified two clones having the proper Xba I restriction pattern (fragments of 7.5 kb, 0.81 kb, and 0.65 kb) and lacking a Sal I restriction site (which was present in the deleted region of the BARl-proinsulin fusion).
  • RF phage replicative form
  • the S . cerevisiae alcohol dehydrogenase I promoter (hereinafter ADHI promoter; also known as ADCI promoter) was tested for use in directing expression of foreign polypeptides in conjunction with BARl sequences.
  • a plasmid comprising these sequences was constructed.
  • the plasmid pZV50 (FIG. 5B) comprises the S . cerevisiae ADHI promoter, the BARl-proinsulin fusion described above, and the terminator region of the S . cerevisiae triose phosphate isomerase (TPI1) gene (Alber and Kawasaki, J. Molec. Appl. Genet. 1 : 419-434, 1982). It was constructed in the following manner. Referring to FIG.
  • plasmid pAH5 (Ammerer, ibid.) was digested with Hind III and Bam HI and the 1.5 kb ADHI promoter fragment was gel purified. This fragment, together with the Hind III-Eco RI polylinker fragment from pUC13, was inserted into Eco RI, Bam Hl-digested pBR327, using T4 DNA ligase. The resultant plasmid, designated pAM5, was digested with Sph I and Xba I, and the approximately 0.4 kb ADHI promoter fragment was purified on a 2% agarose gel.
  • the TPIl terminator was obtained from plasmid pFGl (Alber and Kawasaki, ibid.). pFGl was digested with Eco RI, the linearized plasmid ends were blunted using DNA polymerase I (Klenow fragment), and Bam HI linker sequences (CGGATCCA) were added. The fragment was digested with Bam HI and religated to produce plasmid pl36. The 700 bp TPIl terminator was purified from p136 as a Xba I-Bam HI fragment.
  • This fragment was inserted into Xba I, Bam Hl-digested YEp13, which was then cut with Hind III, the ends blunted using DNA polymerase I (Klenow fragment), and religated to produce plasmid p270.
  • the TPIl terminator was purified from p270 as a Xba I-Bam HI fragment, and was inserted into Xba I, Bam Hl-digested pUC13 to yield plasmid ml15.
  • Plasmid pZV45 was subsequently digested with Sph I and Bam HI, and the ADHI-BARl- proinsulin-TPI terminator sequence was gel purified. This fragment was inserted into YEp13 which had been digested with Sph I and Bam HI, to produce the S . cerevisiae expression vector pZV50.
  • the S. pombe ADH promoter was obtained from a library of DNA fragments derived from S. pombe strain 972h- (ATCC 24843), which had been cloned into YEp13 as described by Russell and Hall (J. Biol. Chem. 258: 143-149, 1983).
  • the promoter sequence was purified from the library as a 0.75 kb Sph I-Eco RI fragment. This fragment and the Eco RI-Hind III polylinker fragment of pUC12 were ligated into YEp13 which had been digested with Sph I and Hind III. The resulting plasmid is known as pEVP-11.
  • the ADH promoter was purified from pEVP-11 as a Sph I-Xba I fragment.
  • Plasmid pZV33 was digested with Xba I and Bgl II and the ca. 340 bp BARl fragment, which includes the ATG initiation codon, was purified.
  • pZV33 was digested with Bgl II and Sst I, and the BARl-proinsulin fusion sequence was purified. The three fragments were combined with Sph I, Sst I-digested pUC18 to produce plasmid pZV46. As pUC18 is not effective for transformation of S.
  • the BARl signal peptide was tested for its ability to direct the export of ⁇ -factor from a yeast transformant.
  • Several plasmids containing DNA fragments coding for fusion proteins with varying lengths of the BARl protein and 1 or 4 copies of mature ⁇ -factor were constructed. These plasmids were transformed into an a/ ⁇ diploid host strain and the transformants assayed for ⁇ -factor production by the halo assay.
  • Plasmids pSW94, pSW95, pSW96, and pSW97 comprise the S. cerevisiae triose phosphate isomerase (TPIl) promoter, a 355 bp or 767 bp fragment of the BARl gene (comprising 114 or 251 codons of the 5' end of the BARl coding sequence, respectively) and either one or four copies of the alpha-factor (MF ⁇ 1) coding sequence.
  • TTIl triose phosphate isomerase
  • Plasmid pM220 (also known as pM210) was used as the source of the TPIl promoter fragment. E. coli RRI transformed with pM220 has been deposited with ATCC under accession number 39853. Plasmid pM220 was digested with Eco RI and the 0.9 kb fragment comprising the TPI1 promoter was isolated by agarose gel electrophoresis and the ends were blunted with DNA polymerase I (Klenow fragment). Kinased Xba I linkers were added to the fragment, which was then digested with Bgl II and Xba I.
  • Plasmid pDR1107 was constructed by subcloning the 900 bp Bgl II-Eco RI TPI1 promoter fragment of pM220 into pIC7 (Marsh, Erfle and Wykes, Gene 32: 481-485, 1984) to generate plasmid pDRHOl. Plasmid pDRH01 was digested with Hind III and Sph I to isolate the 700 bp partial TPI1 promoter fragment.
  • the plasmid was digested with Hind III and Eco RI and the 0.9 kb fragment was isolated and ligated to a synthetic linker constructed by annealing oligonucleotides ZC708 ( 5' AATTGCTCGAGT 3' ) and ZC709 ( 3' CGAGCTCAGATC 5' ).
  • the linker addition eliminates the Eco RI site at the 3' terminus of the TPIl promoter fragment and adds Xhol and Xba I sites. This fragment was then joined to Hind Ill-Xba I cut pUC13.
  • the resultant plasmid was designated pZV134 ( Figure 8).
  • This plasmid was digested with Eco RI and the 1.7 kb fragment containing MF ⁇ 1 was isolated and ligated into Eco RI cut pUC13.
  • the resultant plasmid, designated pl92, was cleaved with Eco RI and the resultant 1.7 kb MF ⁇ 1 fragment was isolated and digested with Mbo II.
  • the 550 bp Mbo II-Eco RI fragment was isolated and ligated to kinased Sal I linkers. The linkered fragment was cut with Sal I.
  • the resulting 0.3 kb Sal I fragment was ligated into Sal I cut pUC4 (Vieira and Messing, Gene.
  • Plasmid pZV24 (Example 2) was digested with Sph I and Bgl II and the 0.8 kb ADHI promoter-BARl fragment was isolated. Plasmid p489 was cleaved with Bam HI and the 0.3 kb MF ⁇ 1 fragment was isolated. These two fragments were joined in a three part ligation to Sph I+Bam HI cut YEp13. The resultant plasmid was designated pZV69 ( Figure 11).
  • Plasmid pZV71 was digested with Xba I and Pst I and the 1.07 kb fragment was isolated.
  • the ADHI promoter was isolated as a 0.42 kb Sph I-Xba I fragment from pZV24. These two fragments were joined, in a three part ligation, to Sph I+Pst I cut pUC18.
  • the resulting plasmid, pZV73 was digested with Sph I and Bam HI and the 1.5 kb fragment comprising the expression unit was isolated and ligated into the Sph I+Bam HI cut YEp13 to form pZV-75 ( Figure 10).
  • the BARl-MF ⁇ 1 fusion units from pZV69 and pZV75 were subcloned with the TPIl promoter into pUC18 ( Figure 11).
  • Plasmid pZV69 was digested with Eco RI and Bam HI and the 0.55 kb fragment containing the fusion was isolated.
  • the 0.9 kb TPIl promoter fragment was isolated from pZV118 by digestion with Hind III and Eco RI.
  • a three part ligation was done by using the .55 kb BARl-MF ⁇ 1 fragment, the 0.9 kb TPIl promoter fragment and pUC19 cut with Hind III and Bam HI.
  • the resultant plasmid was designated pSW59.
  • Plasmid pZV75 was digested with Eco RI and Bam HI to isolate the 954 bp BARl-MF ⁇ 1 fusion fragment. This BARl-MF ⁇ 1 fragment was ligated in a three part ligation with the 0.9 kb Hind III+Eco RI TPIl promoter fragment and pUC18 cut with Hind III and Bam HI to generate plasmid pSW60.
  • Plasmid pJH66 was linearized with Eco RI and blunt-ended with Klenow fragment.
  • Kinased Bam HI linkers 5' CCGGATCCGG 3' ) were added and excess linkers were removed by digestion with Bam HI before religation.
  • the resultant plasmid, pSW8, was cut with Sal I and Bam HI to isolate the 824 bp fragment encoding amino acids 252 through 525 of BARl.
  • This BARl fragment was fused to a fragment encoding the C-terminal portion of substance P (Munro and Pelham, EMBO J . , 2: 3087-3093, 1984).
  • Plasmid pPM2 containing the synthetic oligonucleotide sequence encoding the dimer form of substance P in M13mp8, was obtained from Munro and Pelham. Plasmid pPM2 was linearized by digestion with Bam HI and Sal I and ligated with the 824 bp BARl fragment. The resultant plasmid pSWl4 was digested with Sal I and Sma I to isolate the 871 - bp BARl- substance P fragment. Plasmid pZV16 ( Figure 10) was cut with Xba I and Sal I to isolate the 767 bp 5' coding sequence of BARl.
  • This fragment was ligated with the 871 bp BARl-substance P fragment in a three part ligation with pUC18 cut with Xba I and Sma I.
  • the resultant plasmid was designated pSW15.
  • Plasmid pSW15 was digested with Xba I and Sma I to isolate the 1.64 kb BARl-substance P fragment.
  • the ADHI promoter was obtained from pRL029, comprising the 0.54 kb Sph I-Eco RI fragment containing the ADHI promoter and 116 bp of the BARl 5' coding region from pZV24 in pUC18.
  • Plasmid pRL029 was digested with Sph I and Xba I. to isolate the 0.42 kb ADHI promoter fragment.
  • the TPIl terminator (Alber and-Kawasaki, J. Mol. - Appl. Gen. 1. 419-434, 1982) was provided as a 0.7 kb Xba I+Eco RI fragment in pUC18.
  • the linearized fragment containing the TPIl terminator and pUC18 with a Klenow filled Xba I end and an Sph I end was ligated with the 0.42 kb ADHI promoter fragment and the 1.64 kb BARl-substance P fragment in a three part ligation to produce plasmid pSW22.
  • Plasmid pSW94 was then constructed ( Figure 13).
  • the 2.3 kb fragment containing the BARl-substance P fusion and the TPIl terminator was isolated from plasmid pSW22 as an Xba I-Sst I fragment.
  • the Hind Ill-Xba I TPIl promoter fragment isolated from pZV134 was joined to the BARl-substance P-TPI1 terminator fragment in a three part ligation with Hind III+SstI cut pUC18.
  • the resultant plasmid, pSW81 was cleaved with Hind III and Eco RI to isolate the 1.02 kb fragment containing the TPIl promoter and the 5' 116 bp of BARl.
  • Plasmid pSW60 was cut with Eco RI and Bam HI to isolate the 954 bp BARl-MF ⁇ 1 fusion fragment. Plasmid pSW81 was cut with Hind III and Eco RI to isolate the 1.02 kb TPIl promoter-BARl fragment which was joined with the BARl-MF ⁇ 1 fusion fragment in a three part ligation into Hind III+Bam HI cut YEp13. The resultant plasmid was designated pSW95.
  • Plasmid pZV16 was digested with Eco RI and Sal I. The isolated 651 bp BARl fragment was ligated with a kinased Hind III-Eco RI BARl specific adaptor (produced by annealing oligonucleotides ZC566:
  • Plasmid pM220 provided the TPIl promoter fused to the MF ⁇ l prepro sequence. Plasmid pM220 was digested with Bgl II and Hind III to isolate the 1.2 kb TPIl promoter-MF ⁇ 1 prepro fragment.
  • the 3' portion of the BARl coding region was obtained by cutting pZV9 with Sal I and Bam HI to isolate the 1.3 kb BARl fragment.
  • the 684 bp Hind Ill-Sal I BARl fragment, the 1.2 kb Bgl II-Hind III TPIl promoter-MF ⁇ 1 prepro fragment and the 1.3 kb Sal I-Bam HI BARl fragment were joined with YEp13 linearized with Bam HI in a four part ligation.
  • the construct with the desired, orientation of promoter and MF ⁇ 1-BARl fusion was designated pZVlOO ( Figure 14).
  • a 1 kb Hind III-Pst I fragment comprising the TPIl promoter and the truncated MF ⁇ l prepro sequence from pM220 was joined to the 0.82 kb MF ⁇ 1 prepro-BARl fragment isolated from pZV102 in a three part ligation with YEp13 cut with Hind III and Bam HI.
  • the resultant plasmid was designated pZV105.
  • Plasmid pZV105 was cleaved with Hind III to isolate the 1.2 kb TPIl promoter-MF ⁇ 1 prepro fragment.
  • Plasmid pZV102 was digested with Hind III to isolate the vector fragment containing the terminal ⁇ -factor copy.
  • Plasmid pSW61 was linearized by a partial digestion with Hind III. Plasmid pZV102 was digested with Hind III to isolate the 0.3 kb BARl-MF ⁇ 1 fragment. This fragment was ligated into the linearized pSW61.
  • the plasmid with the insert in the correct orientation at the Hind III site 264 bp 3' to the MF ⁇ 1 start codon was designated pSW70.
  • Plasmid pSW70 was cleaved with Eco RI and Bam HI to isolate the 361 bp BARl-MF ⁇ 1 fragment.
  • Plasmid pSW81 ( Figure 13) was digested with Hind III and Eco RI to isolate the 1.02 kb TPIl promoter-BARl fragment. This fragment was joined to the BARl-MF ⁇ 1 fragment in a three part ligation with YEp13 linearized with Hind III and Bam HI.
  • the resultant plasmid, pSW96 contains the TPIl promoter and 356 bp of the 5' coding sequence of BARl fused to one copy of the ⁇ -factor coding sequence.
  • the second BARl-MF ⁇ 1 construct containing 767 bp of BARl fused to one copy of the MF ⁇ 1 coding sequence was made using pZV75 as the source of the BARl fragment ( Figure 17).
  • Plasmid pZV75 was digested with Eco RI and Bam HI to isolate the 954 bp BARl-MF ⁇ 1 fragment.
  • Plasmid pZV101, containing the MF ⁇ l prepro sequence fused to BARl. was cut with Pst I and Eco RI to isolate the 0.27 kb MF ⁇ 1 prepro-BARl fragment.
  • This fragment was joined to the 954 bp BARl-MF ⁇ 1 fragment in a three part ligation with pUC13 linearized with Pst I and Bam HI.
  • the resultant plasmid, pZV104 was cleaved with Hind III to isolate the 0.70 kb BARl-MF ⁇ 1 fragment.
  • This fragment was ligated to pSW61 which was linearized by partial digestion with Hind III.
  • the plasmid with the insert in the correct orientation at the Hind III site 264 bp 3' to the start codon of MF ⁇ 1 was designated pSW74. Plasmid pSW74 was cut with Eco RI and Bam HI to isolate the 738 bp BARl-MF ⁇ 1 fragment.
  • Plasmid pSW81 was cut with Hind III and Eco RI to isolate the 1.02 kb TPIl promoter-BARl fragment. This fragment was joined to the 738 bp BARl-MF ⁇ 1 fragment in a three part ligation with Hind III+Bam HI cut YEp13.
  • the resultant plasmid, pSW97 contains the TPIl promoter and 767 bp of the 5' end of BARl fused to the single copy of the ⁇ -factor coding sequence.
  • Plasmid pSW73 comprises the TPIl promoter, MF ⁇ 1 signal peptide and prepro sequence and the coding region for the four copies of ⁇ -factor in YEp13.
  • the transformants were spotted onto a lawn of
  • Plasmid pSW67 comprising the TPIl promoter, MF ⁇ l signal peptide, prepro and the coding region for one copy of ⁇ -factor in YEpl3 was used as a control for plasmids pSW96 and pSW97.
  • Plasmids pSW98 and pSW99 are YEp13-based plasmids comprising the S. cerevisiae TPIl promoter, a 355 bp or 767 bp fragment of the BARl gene, including the mutated signal peptide cleavage site, and one copy of the ⁇ -factor coding sequence.
  • the signal peptide mutation was introduced by standard in vitro mutagenesis methods (Zoller et al., Manual for Advanced Techniques in Molecular Cloning Course, Cold Spring Harbor Laboratory, 1983) using a phage M13 template and a synthetic mutageni ⁇ oligonucleotide (sequence 5'ATTACTGCTCCTACAAACGAT3').
  • the phage template pSW54 was constructed by ligating the 0.54 kb
  • Sph I-Eco RI fragment of pSW22 with Sph I-Eco RI digested M13mp19 Following in vitro mutagenesis, potentially mutagenized plaques were screened by plaque hybridization wi.th 32 P-labeled mutagenic oligonucleotide and were sequenced to confirm the presence of the mutation.
  • plasmid pSW82 was digested with Hind III and Eco RI and with Bgl II and Eco RI and the resulting 1.02- kb fragments were isolated.
  • the Hind III-Eco RI fragment of pSW82 was ligated with the Eco RI-Bam HI fragment of pSW74 and Hind III+Bam HI digested YEpl3 to form pSW99.
  • the Bgl II-Eco RI fragment of pSW82 was ligated with the 0.30 kb Eco RI-Bam HI fragment of pSW70 and Bam HI digested YEp13, to form pSW98.
  • Plasmid pSW98 includes the TPIl promoter, 355 bp of the 5' end of the mutagenized BARl sequence and a single copy of the ⁇ -factor coding sequence. Plasmid pSW99 contains the identical expression unit except for having 767 bp of the mutagenized BARl sequence.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procédé de production d'une protéine étrangère dans un organisme hôte, la protéine étant élaborée par l'intermédiaire des voies sécrétrices de l'hôte. La production et l'élaboration sont réalisées en transformant l'organisme hôte avec un vecteur comprenant au moins la région de codage du peptide signal du gêne de la levure S. cerevisiae BAR1 fusionné avec un gêne structural étranger. Les structures d'ADN et des agents de transformation sont également prévus et contiennent une région du gêne BAR1 codant le peptide du signal et un site de traitement KEX2, et un gêne structural étranger en particulier, la proinsuline est exprimée et sécrétée à partir de Schizosaccharomyces pombe et Saccharomyces cerevisiae.
PCT/US1986/002198 1985-10-25 1986-10-20 Procede d'utilisation de bar1 pour la secretion de proteines etrangeres Ceased WO1987002670A1 (fr)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SU864203156A RU2091490C1 (ru) 1985-10-25 1986-10-20 Способ получения гетерологичного полипептида в эукариотических микроорганизмов
UA4203156A UA41863C2 (uk) 1985-10-25 1986-10-20 Спосіб одержання гетерологічного поліпептиду в еукаріотичних мікроорганізмах
HU865248A HU206897B (en) 1985-10-25 1986-10-20 Process for utilizing bar-1 gen for selecting strange proteins
IE280486A IE63822B1 (en) 1985-10-25 1986-10-23 Method of using bar1 for secreting foreign proteins
ES86114769T ES2056785T3 (es) 1985-10-25 1986-10-24 Metodo de utilizacion de bar1 para la secrecion de proteinas extrañas.
AT86114769T ATE107357T1 (de) 1985-10-25 1986-10-24 Verfahren zur verwendung von bar1 für die fremdproteinsekretion.
EP86114769A EP0220689B1 (fr) 1985-10-25 1986-10-24 Méthode permettant l'utilisation de BAR1 pour la sécrétion de protéines étrangères
DE3689918T DE3689918T2 (de) 1985-10-25 1986-10-24 Verfahren zur Verwendung von BAR1 für die Fremdproteinsekretion.
CN86107554A CN1027179C (zh) 1985-10-25 1986-10-25 利用啤酒酵母基因bari分泌异种蛋白的方法
CS867764A CZ284251B6 (cs) 1985-10-25 1986-10-27 Způsob výroby heterologního proteinu v transformované buňce
SK7764-86A SK776486A3 (en) 1985-10-25 1986-10-27 Dna construct, a transformed cell and method for producing an extraneous protein in the transformed cell
DK320287A DK320287A (da) 1985-10-25 1987-06-23 Fremgangsmaade til anvendelse af barl til udskillelse af fremmede proteiner
FI872801A FI872801A0 (fi) 1985-10-25 1987-06-24 Foerfarande foer anvaendning av bar1 foer avsoendring av fraemmande proteiner.

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US79130585A 1985-10-25 1985-10-25
US791,305 1985-10-25

Publications (1)

Publication Number Publication Date
WO1987002670A1 true WO1987002670A1 (fr) 1987-05-07

Family

ID=25153298

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1986/002198 Ceased WO1987002670A1 (fr) 1985-10-25 1986-10-20 Procede d'utilisation de bar1 pour la secretion de proteines etrangeres

Country Status (13)

Country Link
EP (1) EP0243465A1 (fr)
JP (1) JP2523562B2 (fr)
CN (1) CN1027179C (fr)
AU (2) AU6543286A (fr)
CA (1) CA1316133C (fr)
CZ (1) CZ284251B6 (fr)
DK (1) DK320287A (fr)
FI (1) FI872801A0 (fr)
HU (1) HU206897B (fr)
IE (1) IE63822B1 (fr)
SK (1) SK776486A3 (fr)
UA (1) UA41863C2 (fr)
WO (1) WO1987002670A1 (fr)

Cited By (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206699A (en) * 1988-05-06 1993-04-27 Gersan Establishment Sensing a narrow frequency band of radiation and gemstones
WO1995002059A1 (fr) * 1993-07-08 1995-01-19 Novo Nordisk A/S Structure d'adn codant le peptide signal de yap3
US5695965A (en) * 1990-03-13 1997-12-09 Hawaii Biotechnology Group, Inc. Neurospora expression system
WO2002077218A1 (fr) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Derives du facteur vii de coagulation
WO2003027147A2 (fr) 2001-09-27 2003-04-03 Novo Nordisk Health Care Ag Polypeptides de facteur vii de coagulation humain
EP1683860A2 (fr) 1995-03-17 2006-07-26 Novozymes A/S Nouvelles endoglucanases
WO2007020256A1 (fr) 2005-08-16 2007-02-22 Novo Nordisk A/S Procede permettant de realiser des polypeptides d'insuline matures
US7232568B2 (en) 2001-06-05 2007-06-19 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
WO2008030558A2 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
WO2008037735A1 (fr) 2006-09-27 2008-04-03 Novo Nordisk A/S Procédé de fabrication de polypeptides d'insuline mature
EP1975177A1 (fr) 1996-03-01 2008-10-01 Novo Nordisk A/S Peptide de suppression de l'appétit, ses compositions et son utilisation
EP1982732A2 (fr) 2000-02-11 2008-10-22 Maxygen Holdings Ltd. Molécules de type facteur VII ou VIIA
WO2009067636A2 (fr) 2007-11-20 2009-05-28 Ambrx, Inc. Polypeptides d'insuline modifiés et leurs utilisations
EP2080771A2 (fr) 2001-02-27 2009-07-22 Maxygen Aps Nouvelles molécules de type interféron beta
EP2133098A1 (fr) 2000-01-10 2009-12-16 Maxygen Holdings Ltd Conjugués G-CSF
WO2010011735A2 (fr) 2008-07-23 2010-01-28 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
WO2010075475A1 (fr) 2008-12-23 2010-07-01 Abbott Laboratories Anticorps tyrosine kinase du type fms soluble (sflt-1) et composition associée, trousse, procédés d'utilisation, matériaux et procédé de fabrication
WO2010103038A1 (fr) 2009-03-11 2010-09-16 Novo Nordisk A/S Variants de l'interleukine 21 se liant de manière antagoniste au récepteur de l'il-21
WO2011006982A2 (fr) 2009-07-17 2011-01-20 Rigshospitalet Inhibiteurs de l'activation du complément
EP2316930A1 (fr) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Polypéptides humains du facteur de coagulation VII
WO2011067283A1 (fr) 2009-12-01 2011-06-09 Novo Nordisk A/S Nouvelles peptidyl a-hydroxyglycine a-amide lyases
EP2360181A1 (fr) 2005-04-18 2011-08-24 Novo Nordisk A/S Variants de IL-21
WO2011107591A1 (fr) 2010-03-05 2011-09-09 Rigshospitalet Molécules chimériques inhibitrices d'activation du complément
WO2011116023A1 (fr) 2010-03-18 2011-09-22 Abbott Laboratories Procédé permettant d'analyser la lipocaline urinaire associée à la gélatinase des polynucléaires neutrophiles (ungal) dans le pronostic de la fonction de transplantation rénale cadavérique chez un patient, y compris un patient chez lequel a été diagnostiquée une reprise retardée de la fonction du greffon (dgf), procédé permettant d'analyser la ungal dans l'évaluation du risque de dgf chez un patient chez lequel a été diagnostiquée une reprise avancée de la fonction du greffon (egf), et kits afférents
EP2392655A2 (fr) 2003-09-09 2011-12-07 Novo Nordisk Health Care AG Polypeptides de facteur VII à coagulation
WO2011163558A1 (fr) 2010-06-25 2011-12-29 Abbott Laboratories Matériaux et procédés pour le dosage d'anticorps anti-virus de l'hépatite c (hvc)
EP2407561A2 (fr) 2006-03-06 2012-01-18 Humagene, Inc. Procédé de préparation de fibrinogène humaine recombinante
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2012024452A2 (fr) 2010-08-17 2012-02-23 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
WO2012064674A1 (fr) 2010-11-09 2012-05-18 Abbott Laboratories Matériels et méthodes pour un immunoessai permettant d'analyser les ptérines
WO2012076715A1 (fr) 2010-12-09 2012-06-14 Institut Pasteur Procédé à base de mgmt permettant d'obtenir une expression élevée de protéines recombinées
WO2013083847A2 (fr) 2011-12-09 2013-06-13 Institut Pasteur Immunoessai de dépistage multiplex
WO2013102149A1 (fr) 2011-12-31 2013-07-04 Abbott Laboratories Protéine de liaison de la vitamine d humaine tronquée et mutation et fusion de celle-ci, et matériaux associés et procédés d'utilisation
WO2013117705A1 (fr) 2012-02-09 2013-08-15 Var2 Pharmaceuticals Aps Ciblage de glycanes de sulfate de chondroïtine
WO2014060401A1 (fr) 2012-10-15 2014-04-24 Novo Nordisk Health Care Ag Polypeptides de facteur vii de coagulation
EP2805964A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
EP2805965A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
WO2019213331A1 (fr) 2018-05-01 2019-11-07 Ambrx, Inc. Procédé d'optimisation de l'expression d'anticorps
WO2020012021A1 (fr) 2018-07-13 2020-01-16 Varct Diagnostics Aps Isolement de cellules circulantes d'origine fœtale à l'aide d'une protéine de malaria recombinante var2csa
WO2020056066A1 (fr) 2018-09-11 2020-03-19 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-2 et leurs utilisations
WO2020082057A1 (fr) 2018-10-19 2020-04-23 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-10, dimères de ceux-ci et leurs utilisations
WO2020168017A1 (fr) 2019-02-12 2020-08-20 Ambrx, Inc. Contenant de compositions, procédés et utilisations de conjugués anticorps-agonistes tlr
WO2021183832A1 (fr) 2020-03-11 2021-09-16 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-2 et leurs procédés d'utilisation
WO2021211331A1 (fr) 2020-04-13 2021-10-21 Abbott Point Of Care Inc. Procédés, complexes et kits pour détecter ou déterminer une quantité d'un anticorps anti-ss-coronavirus dans un échantillon
WO2022031804A1 (fr) 2020-08-04 2022-02-10 Abbott Laboratories Méthodes et kits améliorés pour détecter une protéine sars-cov-2 dans un échantillon
WO2022040596A1 (fr) 2020-08-20 2022-02-24 Ambrx, Inc. Conjugués anticorps-agonistes de tlr, procédés et utilisations de ceux-ci
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
WO2022147147A1 (fr) 2020-12-30 2022-07-07 Abbott Laboratories Procédés pour déterminer un antigène sras-cov-2 et anticorps anti-sras-cov-2 dans un échantillon
WO2022212899A1 (fr) 2021-04-03 2022-10-06 Ambrx, Inc. Conjugués anticorps-médicament anti-her2 et leurs utilisations
CN115806889A (zh) * 2022-09-28 2023-03-17 山东大学 一种提高基因表达水平的酿酒酵母工程菌及其构建方法与应用

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK58285D0 (da) * 1984-05-30 1985-02-08 Novo Industri As Peptider samt fremstilling og anvendelse deraf
FI96121C (fi) * 1987-10-02 1996-05-10 Zymogenetics Inc DNA-rakenne ja menetelmä heterologisen proteiinin tuottamiseksi
JP3092811B2 (ja) * 1988-07-23 2000-09-25 デルタ バイオテクノロジー リミテッド ペプチドおよびｄｎａ配列
JP2014128262A (ja) * 2012-11-27 2014-07-10 Kirin Brewery Co Ltd 接合能を持つ酵母細胞株のスクリーニング方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4613572A (en) * 1983-08-15 1986-09-23 Kansas State University Research Foundation Yeast BAR1 gene plasmid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3537176C2 (de) * 1984-10-18 1994-06-09 Zymogenetics Inc Gewebeplasminogenaktivator und Verfahren zu seiner Herstellung
JPS61247384A (ja) * 1984-10-18 1986-11-04 チモ−ジエネテイツクス　インコ−ポレ−テツド 酵母中でプラスミノ−ゲン活性化因子を発現する方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4546082A (en) * 1982-06-17 1985-10-08 Regents Of The Univ. Of California E. coli/Saccharomyces cerevisiae plasmid cloning vector containing the alpha-factor gene for secretion and processing of hybrid proteins
US4613572A (en) * 1983-08-15 1986-09-23 Kansas State University Research Foundation Yeast BAR1 gene plasmid

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Journal of Bacteriology (Washington, DC, USA) Volume 155, issued July 1983 (MANNEY) "Expression of the BARI Gene in Saccharomyces Cerevisiae: Induction by the alpha Mating Pheromone of an Activity Associated with a Secreted Protein". *
Journal of Molecular and Applied Genetics (New York, USA) Volume 1, issued 1982 (ALBER et al) "Nucleotide Sequence of Triose Phosphate Isomerase" see pages 419-434. *
Methods in Enzymology (New York, USA) (AMMERER) issued 30 June 1983 "Expression of Genes in Yeast using the ADCI Promoter" see pages 195 to 198. *

Cited By (71)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5206699A (en) * 1988-05-06 1993-04-27 Gersan Establishment Sensing a narrow frequency band of radiation and gemstones
US5695965A (en) * 1990-03-13 1997-12-09 Hawaii Biotechnology Group, Inc. Neurospora expression system
WO1995002059A1 (fr) * 1993-07-08 1995-01-19 Novo Nordisk A/S Structure d'adn codant le peptide signal de yap3
US5726038A (en) * 1993-07-08 1998-03-10 Novo Nordisk A/S DNA construct encoding the YAP3 signal peptide
KR100245173B1 (en) * 1993-07-08 2000-02-15 Novo Nordisk As A dna construct encoding the yap3 signal peptide
EP2431462A2 (fr) 1995-03-17 2012-03-21 Novozymes A/S Nouvelles endoglucanases
EP1683860A2 (fr) 1995-03-17 2006-07-26 Novozymes A/S Nouvelles endoglucanases
EP1975177A1 (fr) 1996-03-01 2008-10-01 Novo Nordisk A/S Peptide de suppression de l'appétit, ses compositions et son utilisation
EP2295453A2 (fr) 1996-03-01 2011-03-16 Novo Nordisk A/S Peptide de suppression de l'appétit, ses compositions et son utilisation
EP2133098A1 (fr) 2000-01-10 2009-12-16 Maxygen Holdings Ltd Conjugués G-CSF
EP1982732A2 (fr) 2000-02-11 2008-10-22 Maxygen Holdings Ltd. Molécules de type facteur VII ou VIIA
EP2319541A1 (fr) 2000-02-11 2011-05-11 Bayer HealthCare LLC Conjugués de type facteur VII ou VIIA
EP2080771A2 (fr) 2001-02-27 2009-07-22 Maxygen Aps Nouvelles molécules de type interféron beta
WO2002077218A1 (fr) 2001-03-22 2002-10-03 Novo Nordisk Health Care Ag Derives du facteur vii de coagulation
US7232568B2 (en) 2001-06-05 2007-06-19 Advanced Biotherapy, Inc. Compositions and methods for treating hyperimmune response in the eye
WO2003027147A2 (fr) 2001-09-27 2003-04-03 Novo Nordisk Health Care Ag Polypeptides de facteur vii de coagulation humain
EP2392655A2 (fr) 2003-09-09 2011-12-07 Novo Nordisk Health Care AG Polypeptides de facteur VII à coagulation
EP2360181A1 (fr) 2005-04-18 2011-08-24 Novo Nordisk A/S Variants de IL-21
WO2007020256A1 (fr) 2005-08-16 2007-02-22 Novo Nordisk A/S Procede permettant de realiser des polypeptides d'insuline matures
EP2316930A1 (fr) 2005-09-14 2011-05-04 Novo Nordisk Health Care AG Polypéptides humains du facteur de coagulation VII
EP2407561A2 (fr) 2006-03-06 2012-01-18 Humagene, Inc. Procédé de préparation de fibrinogène humaine recombinante
WO2008030558A2 (fr) 2006-09-08 2008-03-13 Ambrx, Inc. Polypeptide plasmatique humain modifié ou squelettes de fc et leurs utilisations
WO2008037735A1 (fr) 2006-09-27 2008-04-03 Novo Nordisk A/S Procédé de fabrication de polypeptides d'insuline mature
US8114630B2 (en) 2007-05-02 2012-02-14 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2009067636A2 (fr) 2007-11-20 2009-05-28 Ambrx, Inc. Polypeptides d'insuline modifiés et leurs utilisations
EP2930182A1 (fr) 2007-11-20 2015-10-14 Ambrx, Inc. Polypeptides d'insuline modifiés et utilisations de ceux-ci
EP3225248A1 (fr) 2008-07-23 2017-10-04 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
WO2010011735A2 (fr) 2008-07-23 2010-01-28 Ambrx, Inc. Polypeptides g-csf bovins modifiés et leurs utilisations
US10138283B2 (en) 2008-07-23 2018-11-27 Ambrx, Inc. Modified bovine G-CSF polypeptides and their uses
WO2010075475A1 (fr) 2008-12-23 2010-07-01 Abbott Laboratories Anticorps tyrosine kinase du type fms soluble (sflt-1) et composition associée, trousse, procédés d'utilisation, matériaux et procédé de fabrication
WO2010103038A1 (fr) 2009-03-11 2010-09-16 Novo Nordisk A/S Variants de l'interleukine 21 se liant de manière antagoniste au récepteur de l'il-21
EP3395828A1 (fr) 2009-07-17 2018-10-31 Rigshospitalet Inhibiteurs d'activation complémentaire
WO2011006982A2 (fr) 2009-07-17 2011-01-20 Rigshospitalet Inhibiteurs de l'activation du complément
WO2011067283A1 (fr) 2009-12-01 2011-06-09 Novo Nordisk A/S Nouvelles peptidyl a-hydroxyglycine a-amide lyases
EP2805964A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
EP2805965A1 (fr) 2009-12-21 2014-11-26 Ambrx, Inc. Polypeptides modifiés de somatotrophine bovine et leurs utilisations
EP3815708A1 (fr) 2010-03-05 2021-05-05 Omeros Corporation Molécules chimères inhibitrices de l'activation du complément
WO2011107591A1 (fr) 2010-03-05 2011-09-09 Rigshospitalet Molécules chimériques inhibitrices d'activation du complément
WO2011116023A1 (fr) 2010-03-18 2011-09-22 Abbott Laboratories Procédé permettant d'analyser la lipocaline urinaire associée à la gélatinase des polynucléaires neutrophiles (ungal) dans le pronostic de la fonction de transplantation rénale cadavérique chez un patient, y compris un patient chez lequel a été diagnostiquée une reprise retardée de la fonction du greffon (dgf), procédé permettant d'analyser la ungal dans l'évaluation du risque de dgf chez un patient chez lequel a été diagnostiquée une reprise avancée de la fonction du greffon (egf), et kits afférents
WO2011163558A1 (fr) 2010-06-25 2011-12-29 Abbott Laboratories Matériaux et procédés pour le dosage d'anticorps anti-virus de l'hépatite c (hvc)
US9551714B2 (en) 2010-06-25 2017-01-24 Abbott Laboratories Materials and methods for assay of anti-hepatitis C virus (HCV) antibodies
EP4302783A2 (fr) 2010-08-17 2024-01-10 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
WO2012024452A2 (fr) 2010-08-17 2012-02-23 Ambrx, Inc. Polypeptides de relaxine modifiés et leurs utilisations
US12138296B2 (en) 2010-09-23 2024-11-12 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
US11273202B2 (en) 2010-09-23 2022-03-15 Elanco Us Inc. Formulations for bovine granulocyte colony stimulating factor and variants thereof
WO2012064674A1 (fr) 2010-11-09 2012-05-18 Abbott Laboratories Matériels et méthodes pour un immunoessai permettant d'analyser les ptérines
EP3202897A1 (fr) 2010-12-09 2017-08-09 Institut Pasteur Procédé de type mgmt pour obtenir un rendement élevé d'expression de protéine recombinante
WO2012076715A1 (fr) 2010-12-09 2012-06-14 Institut Pasteur Procédé à base de mgmt permettant d'obtenir une expression élevée de protéines recombinées
US10352930B2 (en) 2011-12-09 2019-07-16 Institut Pasteur Multiplex immuno screening assay
WO2013083847A2 (fr) 2011-12-09 2013-06-13 Institut Pasteur Immunoessai de dépistage multiplex
US10197562B2 (en) 2011-12-09 2019-02-05 Institut Pasteur Multiplex immuno screening assay
US9638692B2 (en) 2011-12-09 2017-05-02 Institut Pasteur Multiplex immuno screening assay
WO2013102149A1 (fr) 2011-12-31 2013-07-04 Abbott Laboratories Protéine de liaison de la vitamine d humaine tronquée et mutation et fusion de celle-ci, et matériaux associés et procédés d'utilisation
WO2013117705A1 (fr) 2012-02-09 2013-08-15 Var2 Pharmaceuticals Aps Ciblage de glycanes de sulfate de chondroïtine
WO2014060401A1 (fr) 2012-10-15 2014-04-24 Novo Nordisk Health Care Ag Polypeptides de facteur vii de coagulation
WO2019213331A1 (fr) 2018-05-01 2019-11-07 Ambrx, Inc. Procédé d'optimisation de l'expression d'anticorps
US12404512B2 (en) 2018-05-01 2025-09-02 Ambrx, Inc. Method for optimizing antibody expression
WO2020012021A1 (fr) 2018-07-13 2020-01-16 Varct Diagnostics Aps Isolement de cellules circulantes d'origine fœtale à l'aide d'une protéine de malaria recombinante var2csa
WO2020056066A1 (fr) 2018-09-11 2020-03-19 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-2 et leurs utilisations
US12049485B2 (en) 2018-09-11 2024-07-30 Ambrx, Inc. Interleukin-2 polypeptide conjugates and their uses
EP4389145A2 (fr) 2018-09-11 2024-06-26 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-2 et leurs utilisations
WO2020082057A1 (fr) 2018-10-19 2020-04-23 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-10, dimères de ceux-ci et leurs utilisations
WO2020168017A1 (fr) 2019-02-12 2020-08-20 Ambrx, Inc. Contenant de compositions, procédés et utilisations de conjugués anticorps-agonistes tlr
WO2021183832A1 (fr) 2020-03-11 2021-09-16 Ambrx, Inc. Conjugués polypeptidiques d'interleukine-2 et leurs procédés d'utilisation
WO2021211331A1 (fr) 2020-04-13 2021-10-21 Abbott Point Of Care Inc. Procédés, complexes et kits pour détecter ou déterminer une quantité d'un anticorps anti-ss-coronavirus dans un échantillon
WO2022031804A1 (fr) 2020-08-04 2022-02-10 Abbott Laboratories Méthodes et kits améliorés pour détecter une protéine sars-cov-2 dans un échantillon
WO2022040596A1 (fr) 2020-08-20 2022-02-24 Ambrx, Inc. Conjugués anticorps-agonistes de tlr, procédés et utilisations de ceux-ci
WO2022147147A1 (fr) 2020-12-30 2022-07-07 Abbott Laboratories Procédés pour déterminer un antigène sras-cov-2 et anticorps anti-sras-cov-2 dans un échantillon
WO2022212899A1 (fr) 2021-04-03 2022-10-06 Ambrx, Inc. Conjugués anticorps-médicament anti-her2 et leurs utilisations
CN115806889A (zh) * 2022-09-28 2023-03-17 山东大学 一种提高基因表达水平的酿酒酵母工程菌及其构建方法与应用
CN115806889B (zh) * 2022-09-28 2024-06-11 山东大学 一种提高基因表达水平的酿酒酵母工程菌及其构建方法与应用

Also Published As

Publication number Publication date
HU206897B (en) 1993-01-28
JP2523562B2 (ja) 1996-08-14
DK320287D0 (da) 1987-06-23
JPS63501614A (ja) 1988-06-23
CA1316133C (fr) 1993-04-13
EP0243465A1 (fr) 1987-11-04
AU7400391A (en) 1991-07-18
CZ776486A3 (en) 1996-09-11
UA41863C2 (uk) 2001-10-15
CN1027179C (zh) 1994-12-28
HUT43624A (en) 1987-11-30
SK279041B6 (sk) 1998-06-03
AU676132B2 (en) 1997-03-06
SK776486A3 (en) 1998-06-03
FI872801A7 (fi) 1987-06-24
CZ284251B6 (cs) 1998-10-14
IE63822B1 (en) 1995-06-14
DK320287A (da) 1987-06-23
CN86107554A (zh) 1987-08-26
FI872801A0 (fi) 1987-06-24
IE862804L (en) 1987-04-25
AU6543286A (en) 1987-05-19

Similar Documents

Publication Publication Date Title
CA1316133C (fr) Methodes d'utilisation du gene bar1 pour la secretion de proteines etrangeres
CA1340772C (fr) Expression et secretion de proteines heterologues dans une levure au moyen de sequences leader tronquees du facteur alpha
US5037743A (en) BAR1 secretion signal
CA1340547C (fr) Nouvelles sequences-guides de secretion pour levures
EP0123544A2 (fr) Procédé d'expression de protéines hétérologues dans les levures, vecteurs d'expression et micro-organismes du genre levure à cet effet
EP0548267A1 (fr) Production du facteur-1 de croissance similaire a l'insuline dans des cellules de levure methylotrophique
EP0220689B1 (fr) Méthode permettant l'utilisation de BAR1 pour la sécrétion de protéines étrangères
US5612198A (en) Production of insulin-like growth factor-1 in methylotrophic yeast cells
CA2085308C (fr) Endoprotease dibasique fusionne au signal de retention reticulum endoplasmique et utilisation
US7198919B1 (en) Use of alpha factor sequences in yeast expression systems
JP3135550B2 (ja) 成熟異種タンパク質、特にヒルジン、の製造のための改良された酵母株、および対応するヒルジンの製造法
JP4180112B2 (ja) 酵母細胞におけるｎ末端を伸長されたタンパクの発現のためのベクター
EP0310137B1 (fr) Séquence signal BAR1
US5879926A (en) Yeast strains for the production of mature heterologous proteins, especially hirudin
EP1097228B1 (fr) Technique de production de proteines dans des cellules de levure transformees
WO1991002057A1 (fr) Production de polypeptides a l'interieur de cellules fongiques

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AU DK FI HU JP SU US

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 872801

Country of ref document: FI